OPK

OPKO Health, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · opko.com

$1.13

Pre-mkt $1.14 +0.88%

Mkt Cap $853.3M

52w Low $0.98 24.2% of range 52w High $1.60

50d MA $1.17 200d MA $1.31

P/E (TTM) -3.8x

EV/EBITDA -21.2x

P/B 0.7x

Debt/Equity 0.3x

ROE -1.5%

P/FCF -5.1x

RSI (14) —

ATR (14) —

Beta 1.49

50d MA $1.17

200d MA $1.31

Avg Volume 2.5M

About

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, m… OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 28, 2026	AMC	-0.07	-0.07	+0.0%	1.21	-3.3%	-8.3%	-6.6%	-9.1%	-8.3%	-7.4%	—
Feb 26, 2026	AMC	-0.07	-0.04	+42.9%	1.20	-0.8%	+0.0%	+3.3%	-0.8%	+0.0%	-2.5%	—
Oct 29, 2025	AMC	-0.02	0.03	+250.0%	1.43	-2.1%	+2.1%	-4.9%	-2.1%	-2.8%	-6.3%	—
Jul 31, 2025	AMC	-0.12	-0.19	-58.3%	1.28	-4.7%	-7.0%	-0.8%	-1.6%	-0.8%	-3.9%	—
Apr 30, 2025	AMC	-0.06	-0.10	-66.7%	1.38	-5.1%	-2.2%	+0.7%	-1.4%	-7.2%	-9.4%	—
Feb 27, 2025	AMC	-0.08	0.01	+112.5%	1.63	+4.3%	+6.7%	+7.4%	+17.8%	+19.0%	+16.0%	—
Nov 7, 2024	AMC	-0.10	0.03	+130.0%	1.45	+0.7%	+4.8%	+8.3%	+11.0%	+10.3%	+11.7%	—
Aug 7, 2024	AMC	-0.09	-0.01	+88.9%	1.28	+6.2%	+11.7%	+17.2%	+17.2%	+18.8%	+19.5%	—
May 7, 2024	AMC	-0.09	-0.12	-33.3%	1.30	-10.0%	-3.8%	-3.1%	-1.5%	-3.1%	+0.8%	—
Feb 27, 2024	AMC	-0.09	-0.09	+0.0%	1.05	-4.8%	-6.1%	-4.8%	-5.4%	-4.8%	-11.0%	—
Nov 6, 2023	AMC	-0.09	-0.11	-22.2%	1.34	-3.0%	+0.0%	+0.0%	-4.5%	-6.0%	-4.5%	—
Aug 3, 2023	AMC	-0.07	-0.03	+57.1%	1.85	+7.0%	+7.6%	-1.6%	+1.6%	-4.3%	-1.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 29	Barrington Research	Downgrade	Outperform → Mkt Perform	—	$1.21	$1.17	-3.3%	-8.3%	-6.6%	-9.1%	—	—
Apr 29	Barrington Research	Downgrade	Outperform → Market Perform	—	$1.21	$1.17	-3.3%	-8.3%	-6.6%	-9.1%	—	—
Mar 2	Barrington Research	Maintains	Outperform → Outperform	—	$1.20	$1.19	-0.8%	+3.3%	-0.8%	+0.0%	-2.5%	-1.7%
Oct 31	Jefferies	Downgrade	Buy → Hold	—	$1.46	$1.42	-2.7%	-6.8%	-4.1%	-4.8%	-8.2%	-5.5%
Oct 30	Barrington Research	Maintains	Outperform → Outperform	—	$1.43	$1.40	-2.1%	+2.1%	-4.9%	-2.1%	-2.8%	-6.3%
May 1	Barrington Research	Maintains	Outperform → Outperform	—	$1.38	$1.31	-5.1%	-2.2%	+0.7%	-1.4%	-7.2%	-9.4%
Apr 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.55	$1.50	-3.2%	-1.3%	-5.8%	-3.9%	-12.3%	-8.4%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.79	$1.76	-1.7%	+3.9%	+1.7%	+0.6%	+1.1%	+0.6%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.80	$1.83	+1.7%	-1.1%	-4.4%	-3.3%	+0.6%	-0.6%
Mar 12	Barrington Research	Maintains	Outperform → Outperform	—	$1.80	$1.83	+1.7%	-1.1%	-4.4%	-3.3%	+0.6%	-0.6%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.74	$1.75	+0.6%	+0.6%	+10.3%	+11.5%	+8.6%	+9.2%
Feb 28	Barrington Research	Maintains	Outperform → Outperform	—	$1.63	$1.70	+4.3%	+6.7%	+7.4%	+17.8%	+19.0%	+16.0%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.51	$1.49	-1.3%	-2.0%	-2.6%	+1.3%	-2.0%	-2.6%
Nov 8	Barrington Research	Maintains	Outperform → Outperform	—	$1.45	$1.46	+0.7%	+4.8%	+8.3%	+11.0%	+10.3%	+11.7%
Sep 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.48	$1.49	+0.7%	+0.7%	+2.7%	+0.7%	+0.7%	+2.7%
Sep 20	Barrington Research	Maintains	Outperform → Outperform	—	$1.59	$1.55	-2.5%	-6.9%	-5.7%	-6.9%	-6.9%	-6.3%
Sep 17	Piper Sandler	Maintains	Overweight → Overweight	—	$1.64	$1.55	-5.5%	+1.2%	-1.2%	-3.0%	-9.8%	-8.5%
Sep 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.64	$1.55	-5.5%	+1.2%	-1.2%	-3.0%	-9.8%	-8.5%
Aug 8	Barrington Research	Maintains	Outperform → Outperform	—	$1.28	$1.36	+6.2%	+11.7%	+17.2%	+17.2%	+18.8%	+19.5%
Jul 18	Piper Sandler	Maintains	Overweight → Overweight	—	$1.42	$1.53	+7.7%	+7.0%	+4.9%	+2.8%	+1.4%	+0.0%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.30	$1.17	-10.0%	-3.8%	-3.1%	-1.5%	-3.1%	+0.8%
Apr 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.35	$1.33	-1.5%	+0.0%	+0.7%	+0.0%	+3.7%	+2.2%
Apr 1	Barrington Research	Maintains	Outperform → Outperform	—	$1.20	$1.20	+0.0%	+9.2%	+12.5%	+12.5%	+13.3%	+12.5%
Apr 1	Piper Sandler	Maintains	Overweight → Overweight	—	$1.20	$1.20	+0.0%	+9.2%	+12.5%	+12.5%	+13.3%	+12.5%
Feb 28	Barrington Research	Maintains	Outperform → Outperform	—	$1.05	$1.00	-4.8%	-6.1%	-4.8%	-5.4%	-4.8%	-11.0%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.05	$1.00	-4.8%	-6.1%	-4.8%	-5.4%	-4.8%	-11.0%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.99	$2.02	+1.5%	-8.5%	-5.5%	-11.1%	-8.5%	-9.0%
Jun 29	Barrington Research	Upgrade	Market Perform → Outperform	—	$1.72	$1.72	+0.0%	+13.7%	+26.2%	+23.8%	+22.1%	+19.8%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.69	$1.71	+1.2%	+8.3%	+10.1%	+9.5%	+8.3%	+5.3%
Mar 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.13	$1.14	+0.9%	+7.1%	+9.7%	+10.6%	+18.6%	+20.4%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.12	$1.08	-3.6%	-5.4%	+0.9%	+1.8%	+4.5%	+7.1%
Dec 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.29	$1.31	+1.6%	-3.1%	-3.1%	-10.9%	-8.5%	-9.3%
Aug 5	Piper Sandler	Maintains	Overweight → Overweight	—	$2.40	$2.30	-4.2%	-5.0%	+2.1%	+4.6%	+12.9%	+4.2%
May 10	Piper Sandler	Maintains	Overweight → Overweight	—	$2.44	$2.55	+4.5%	+20.1%	+10.2%	+14.8%	+24.2%	+21.7%
Jan 24	Barrington Research	Downgrade	Outperform → Market Perform	—	$4.24	$3.53	-16.7%	-23.8%	-29.0%	-31.4%	-32.3%	-30.4%
Jun 21	Ladenburg Thalmann	Maintains	Buy → Buy	—	$3.70	$3.76	+1.6%	+2.2%	+3.8%	+0.0%	+1.9%	+4.3%
Nov 25	Piper Jaffray	Maintains	Overweight → Overweight	—	$1.61	$1.65	+2.5%	+1.2%	-1.2%	+0.0%	-1.2%	-3.1%
Mar 2	JP Morgan	Downgrade	Neutral → Underweight	—	$3.18	$2.67	-16.0%	+6.0%	+11.3%	+7.5%	+4.7%	+4.4%
Sep 14	JP Morgan	Downgrade	Overweight → Neutral	—	$6.47	$6.24	-3.6%	-7.0%	-7.7%	-7.0%	-7.1%	-2.2%
Aug 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.88	$6.07	+3.2%	+4.1%	+4.4%	+5.3%	+4.3%	+7.1%
Mar 14	Guggenheim	Maintains	Buy → Buy	—	$7.92	$8.14	+2.8%	+1.9%	+2.1%	+5.6%	+2.5%	+1.0%
Dec 30	Standpoint Research	Maintains	Buy → Buy	—	$11.46	$9.71	-15.3%	-18.8%	-20.7%	-19.1%	-21.1%	-18.2%
Jun 16	Deutsche Bank	Maintains	Hold → Hold	—	$9.23	$9.07	-1.7%	+0.5%	-2.0%	-0.4%	+5.1%	+1.4%
Jun 3	Standpoint Research	Maintains	Buy → Buy	—	$10.65	$10.64	-0.1%	-6.0%	-5.8%	-7.1%	-8.2%	-9.8%
Mar 31	Barrington Research	Maintains	Outperform → Outperform	—	$9.90	$9.96	+0.6%	+4.9%	+5.2%	+5.1%	+3.8%	+7.9%
Oct 16	JP Morgan	Maintains	Overweight → Overweight	—	$9.28	$9.59	+3.3%	+1.2%	+9.4%	+2.6%	-1.4%	-2.7%
Aug 12	Laidlaw & Co.	Maintains	Buy → Buy	—	$13.45	$13.40	-0.4%	+0.0%	-2.8%	-3.3%	-2.3%	-5.2%
Mar 3	Oppenheimer	Downgrade	Outperform → Perform	—	$14.44	$14.05	-2.7%	-0.3%	-0.5%	-0.8%	-2.3%	-3.2%
Aug 13	Jefferies	Maintains	Buy → Buy	—	$9.08	$9.12	+0.4%	+1.1%	+0.3%	+0.0%	+1.0%	-0.2%
May 12	Oppenheimer	Maintains	Outperform → Outperform	—	$8.24	$8.22	-0.2%	+2.1%	+1.1%	-0.7%	-0.8%	-0.8%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

A board member change at OPK suggests potential shifts in healthcare industry expertise and strategic direction, which investors should monitor for impacts on company governance and operational focus.

Mar 19

8-K

Opko Health Inc. -- 8-K Filing

OPKO Health reported fourth-quarter 2025 results and is hosting a conference call to discuss financial performance and business developments with investors.

Feb 26

8-K · 5.02 !!! Very High

Entera Bio Ltd. -- 8-K 5.02: Executive Change

Steven D. Rubin's appointment as a Class III director at Entera Bio (ENTX) effective February 2026 expands board oversight and may signal management's confidence in governance structure during potential strategic initiatives.

Feb 4

Data updated apr 26, 2026 5:40pm · Source: massive.com